Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer – Medical Xpress
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic cast…
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
General19 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Business21 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000
-
Noosa News21 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
Noosa News21 hours agoGrow it local | Noosa Today